Insiders · KNTE

Michael E Rome

Director at Kinnate Biopharma Inc. (KNTE)

Michael E Rome has filed 2 insider reports with the SEC since June 2022, as director at Kinnate Biopharma Inc. (KNTE). The latest filing, on April 5, 2024, reports sale back to the company at Kinnate Biopharma Inc. (KNTE).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Michael E Rome is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Kinnate Biopharma Inc. logo
KNTE
Kinnate Biopharma Inc.
DirectorApr 5, 2024

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael E Rome with

Questions about Michael E Rome

What is Michael E Rome's role at Kinnate Biopharma Inc.?
Michael E Rome reports to the SEC as director at Kinnate Biopharma Inc. (KNTE), according to the latest filing on April 5, 2024.
Has Michael E Rome bought or sold stock recently?
No open-market purchases or sales by Michael E Rome are on file. The filings report sale back to the company and grant or award.
How do I get alerts when Michael E Rome files?
Follow Michael E Rome on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael E Rome (SEC CIK 0001820818). Totals count each trade once, skipping amendments whose original is on file, from Jun 15, 2022 on. View on SEC EDGAR